Metformin has been the first-line pharmacotherapy for type 2 diabetes mellitus (T2DM) since the UKPDS (United Kingdom Prospective Diabetes Study) established its unique cardiovascular mortality benefit in overweight T2DM patients in 1998. Understanding WHY metformin occupies this position requires knowledge of its mechanism, clinical evidence, safety profile, and how it addresses the core pathophysiology of T2DM. Mechanism of action: Metformin primarily activates AMP-activated protein kinase (AMPK) in hepatocytes, suppressing mitochondrial respiratory chain complex I, which shifts the cellular AMP/ATP ratio and activates AMPK. This (1) inhibits hepatic gluconeogenesis (the dominant mechanism, reducing fasting glucose by decreasing inappropriate overnight glucose production), (2) improves insulin sensitivity in skeletal muscle by increasing GLUT4 transporter expression and translocation, (3) modestly reduces intestinal glucose absorption, and (4) may improve beta-cell function by reducing glucotoxicity. Critically, metformin does NOT stimulate insulin secretion from beta cells -- it works peripherally to overcome insulin resistance. This means it does NOT cause hypoglycemia when used as monotherapy (a major safety advantage over sulfonylureas). Pharmacokinetics: metformin is NOT metabolized by the liver (unusual for an oral medication) and is excreted...